- 2016 healthcare acquired infection treatment market forecast: $30 billion
- Pharmaceutical infection treatments growing at 12% CAGR
- Antibiotic resistance is increasing demand for effective HAI treatments
LONDON--(BUSINESS WIRE)-- The rising incidence of infections acquired in healthcare environments has seen demand for infection related treatments increase. In 2016, the healthcare-acquired infection control market is expected to be worth in excess of $30 billion, having grown from a 2011 figure of $19 billion, at a CAGR of 9.5%. In the US it is estimated that HAI (healthcare-acquired infections) cause the deaths of over 100,000 patients a year, according to a new report available from companiesandmarkets.com.
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
In recent years, there has been a marked increase in the number of patients developing infections following admittance into hospital and other healthcare settings. HAIs are bacterial, fungal or viral infections which can be contracted in several ways: via surgical procedures, routine care, or from use of medical devices such as catheters and IV lines.
The use of exploratory surgery and interventional procedures is also on the rise, increasing potential opportunities for infection. Furthermore, clinicians are also noting rising resistance to antibiotics used to treat infections, compounding demand for effective and safe HAI treatments and technologies.
The largest HAI market segment is infection control devices and products, worth $8.3 billion in 2010; forecast to achieve $10.3 billion by 2011 and $18.3 billion by 2016. This represents a robust 12% CAGR over the reporting period, which is more than double the 5.8% CAGR forecast for the HAI pharmaceutical treatments segment which is expecting to see revenues of $6 billion by 2016.
Included within the study are profiles of key players in the HAI market, from both a medical device and a pharmaceutical perspective. Companies include: Abbott Laboratories, Nabi Biopharmaceuticals, Odine Biomedical, Inc, Theravanc, Advanced Sterilization Products, Bactiguard, AB and Medimmune Pharmaceuticals.
Published in August 2011, the 201 page study examines the HAI market for the period 2010-2016, analysing devices, therapies and pharmaceuticals by treatment area and treatment type. The study will focus on the US, Europe and Japan, as well as The report will include the U.S., Europe, Japan, and other countries such as China.
Report Details:
CONTACT:
Mike King
Press Office
Companies & Markets
[email protected]
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Hospitals Infectious Diseases Communications Marketing
MEDIA:
| Logo |